pill shown to halve the risk of death from a certain type of lung cancer

[gurusforum]

BOOK INTERNATIONAL FLIGHTS TICKETS LOCAL FLIGHTS HOTELS BOOKINGS WORLDWIDE AND MORE AT CHEAPEST RATE EVER! CLICK HERE TO BOOK YOUR FLIGHT AND RECEIVE YOUR FLIGHT TICKET INSTANTLY

A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results presented on Sunday.

The results were unveiled in Chicago at the largest annual conference of cancer specialists, hosted by the American Society for Clinical Oncology.

Lung cancer is the form of the disease that causes the most deaths, with approximately 1.8 million fatalities every year worldwide.

The treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso. It targets a particular type of lung cancer in patients suffering from so-called non-small cell cancer, the most common type, and showing a particular type of mutation.

These mutations, on what is called the epidermal growth factor receptor, or EGFR, affect 10% to 25% of lung cancer patients in the United States and Europe, and 30 to 40% in Asia.

The clinical trial included some 680 participants at an early stage of the disease (stages 1b to 3a), in more than 20 countries. They had to have been operated on first to remove the tumor, then half of the patients took the treatment daily, and the other a placebo.

The result showed that taking the tablet resulted in a 51% reduction in the risk of death for treated patients, compared to placebo.

After five years, 88% of patients who took the treatment were still alive, compared to 78% of patients who took the placebo.